Home/Pipeline/Bria-IMT™ + CPI

Bria-IMT™ + CPI

Metastatic Breast Cancer

Phase 3Active, PivotalNCT06072612

Key Facts

Indication

Metastatic Breast Cancer

Phase

Phase 3

Status

Active, Pivotal

Company

BriaCell Therapeutics

About BriaCell Therapeutics

BriaCell Therapeutics is a clinical-stage biotech focused on developing targeted cellular immunotherapies to transform cancer care. Its core strategy is advancing Bria-IMT™, a Fast Track-designated candidate in a pivotal Phase 3 study for metastatic breast cancer, while expanding its pipeline through the innovative Bria-OTS™ platform, which enables personalized, off-the-shelf treatments. The company has demonstrated promising clinical data, including extended survival in heavily pre-treated patients, and is backed by collaborations with the National Cancer Institute.

View full company profile

Therapeutic Areas

Oncology Immuno-oncology

Other Metastatic Breast Cancer Drugs

Drug	Company	Phase	Status
ZetaMAST (Zeta-MBC-005)	Zetagen Therapeutics	Phase 2	Active
Platin-DRP®	Chosa Oncology	Validation	Active
OP-3136	Olema Oncology	Preclinical	Active
Vectorized-VX-765	Atlanthera	Research	Active
AURORA 2 Project Collaboration	Seqalis	Phase 2	Active
BPI-1178 (Eciruciclib)	Beta Pharma	Phase 3	Active
Herzuma®	Celltrion	Marketed	Approved
Eftilagimod alfa (efti)	Immutep	Phase IIb	Active (AIPAC-003)
(Z)-endoxifen	Atossa Therapeutics	Phase 1/2	Active (Presumed)
Bria-OTS™ (Bria-BRES™)	BriaCell Therapeutics	Phase 1/2	Active, Recruiting